Adropin – physiological and pathophysiological role

Marczuk, Natalia; Cecerska-Heryć, Elżbieta; Jesionowska, Anna; Dołęgowska, Barbara

doi:10.5604/17322693.1220082

Cited by 27 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It plays a role in mechanisms related to increased adiposity, insulin resistance, as well as glucose and lipid metabolism ( 1 ). Adropin is a secretory signal peptide which has been shown to alter whole body glucose and lipid metabolism after administration in mice and rats, and it also activates signaling pathways involved in glucose and lipid metabolism in mammalian cell lines ( 34 , 35 ).…”

Section: Discussionmentioning

confidence: 99%

Adropin Stimulates Proliferation and Inhibits Adrenocortical Steroidogenesis in the Human Adrenal Carcinoma (HAC15) Cell Line

et al. 2020

View full text Add to dashboard Cite

Adropin is a multifunctional peptide hormone encoded by the ENHO (energy homeostasis associated) gene. It plays a role in mechanisms related to increased adiposity, insulin resistance, as well as glucose, and lipid metabolism. The low adropin levels are strongly associated with obesity independent insulin resistance. On the other hand, overexpression or exogenous administration of adropin improves glucose homeostasis. The multidirectional, adropin-related effects associated with the regulation of metabolism in humans also appear to be attributable to the effects of this peptide on the activity of various elements of the endocrine system including adrenal cortex. Therefore, the main purpose of the present study was to investigate the effect of adropin on proliferation and secretory activity in the human HAC15 adrenal carcinoma cell line. In this study, we obtained several highly interesting findings. First, GPR19, the main candidate sensitizer of adrenocortical cells to adropin, was expressed in HAC15 cells. Moreover, GPR19 expression was relatively stable and not regulated by ACTH, forskolin, or adropin itself. Our findings also suggest that adropin has the capacity to decrease expression levels of steroidogenic genes such as steroidogenic acute regulatory protein ( StAR ) and CYP11A1 , which then led to a statistically significant inhibition in cortisol and aldosterone biosynthesis and secretion. Based on whole transcriptome study and research involving transforming growth factor (TGF)-β type I receptor kinase inhibitor we demonstrated that attenuation of steroidogenesis caused by adropin is mediated by the TGF-β signaling pathway likely to act through transactivation mechanism. We found that HAC15 cells treated with adropin presented significantly higher proliferation levels than untreated cells. Using specific intracellular inhibitors, we showed that adropin stimulate proliferation via ERK1/2 and AKT dependent signaling pathways. We have also demonstrated that expression of GPR19 is elevated in adrenocortical carcinoma in relation to normal adrenal glands. High level of GPR19 expression in adrenocortical carcinoma may constitute a negative prognostic factor of disease progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Adropin Stimulates Proliferation and Inhibits Adrenocortical Steroidogenesis in the Human Adrenal Carcinoma (HAC15) Cell Line

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The available data regarding the role of adropin and relationships with the development with metabolic diseases, are inconsistent. Reduced levels of adropin have been observed in obesity-associated insulin resistance, gestational diabetes, nonalcoholic fatty liver disease (NAFLD), acute myocardial infarction, coronary atherosclerosis and endothelial dysfunction [7,8]. Sayin et al have demonstrated that low adropin concentrations were associated with the risk of NAFLD (18).…”

Section: Discussionmentioning

confidence: 99%

“…The most recent studies have shown that plasma concentrations of afamin are strongly correlated with metabolic syndrome indices [6]. Adropin is a peptide hormone involved in energy homeostasis and regulation of metabolism of glucose and fatty acids [7]. It has been suggested that a low serum adropin level may be associated with more severe coronary atherosclerosis [8].…”

Section: Introductionmentioning

confidence: 99%

Afamin and adropin in patients with alcohol-induced liver cirrhosis

Prystupa¹,

Kiciński²,

Luchowska-Kocot³

et al. 2018

Ann Agric Environ Med.

View full text Add to dashboard Cite

The aim of the study was to determine serum concentrations of afamin and adropin in patients with alcoholic liver cirrhosis and to define their correlation with the stage of disease. The study included 99 patients with alcoholic cirrhosis from the region of Lublin, (Eastern Poland). Liver cirrhosis was diagnosed based on clinical features, history of heavy alcohol consumption, laboratory tests and abdominal ultrasonography. The control group consisted of 20 healthy individuals without liver disease who did not abuse alcohol. The serum afamin and adropin concentrations were determined using ELISA kits. The concentration of afamin was found to be significantly lower in patients with compensated alcoholic liver cirrhosis, i.e. P-Ch B (85.1±40.6 μg/ml) and P-Ch C (56.4±32.3 μg/ml) individuals, compared to the control group (135.9±43.6 μg/ml); p-value was <0.01 and <0.001, respectively. As far as adropin is concerned, a reverse relationship was demonstrated: the highest concentration was found in patients with P-Ch C (11.7±5.7 ng/ml) cirrhosis. Furthermore, the above concentration was significantly higher compared to patients with P-Ch A cirrhosis (7.2±2.8 ng/ml; p<0.05) and controls (7.5±2.6 ng/ml; p<0.05). The concentration of afamin decreases with the severity of alcoholic liver cirrhosis, which most likely results from impaired hepatic synthesis. Otherwise, the higher the stage of disease according to the Child-Pugh score, the higher the concentration of adropin.

show abstract

“…It was later shown to be a membrane‐bound protein modulating cell‐cell communication. Adropin is mainly expressed in the liver and the central nervous system (CNS) but can also be found in the kidney, heart, pancreas, small intestine and endothelial cells 4–6 …”

Section: Introductionmentioning

confidence: 99%

Adropin as a potential mediator of the metabolic system‐autonomic nervous system‐chronobiology axis: Implementing a personalized signature‐based platform for chronotherapy

2020

View full text Add to dashboard Cite

Adropin is a peptide hormone, which plays a role in energy homeostasis and controls glucose and fatty acid metabolism. Its levels correlate with changes in carbohydratelipid metabolism, metabolic diseases, central nervous system function, endothelial function and cardiovascular disease. Both metabolic pathways and adropin are regulated by the circadian clocks. Here, we review the roles of the autonomic nervous system and circadian rhythms in regulating metabolic pathways and energy homeostasis. The beneficial effects of chronotherapy in various systems are discussed. We suggest a potential role for adropin as a mediator of the metabolic system-autonomic nervous system axis. We discuss the possibility of establishing an individualized adropin and circadian rhythm-based platform for implementing chronotherapy, and variability signatures for improving the efficacy of adropin-based therapies are discussed. K E Y W O R D S adropin, autonomic nervous system, chronobiology, metabolic syndrome 1 | INTRODUCTION Metabolic syndrome (MetS) is a cluster of metabolic and cardiovascular complications, which increase the risk of cardiovascular diseases (CVD) and type 2 diabetes (T2D). 1 The pathogenesis of MetS involves multiple factors, including the autonomic nervous system (ANS) and the circadian rhythm. 2 Recently, MetS was also shown to increase the risk and mortality of cancer, 3 with which it shares many risk factors including age, genetic factors, obesity, physical inactivity, unhealthy diet, alcohol, smoking, endocrine disruptors exposure and air pollution. Recent studies have suggested that several peptide hormones play important roles in the modulation of systemic metabolism and energy homeostasis. Adropin is a product of the energy homeostasis associated (Enho) gene and a peptide hormone that plays a role in the regulation of energy homeostasis and controls glucose and fatty acid metabolism. It was originally described as a secreted peptide, with

show abstract

Adropin – physiological and pathophysiological role

Cited by 27 publications

References 0 publications

Adropin Stimulates Proliferation and Inhibits Adrenocortical Steroidogenesis in the Human Adrenal Carcinoma (HAC15) Cell Line

Adropin Stimulates Proliferation and Inhibits Adrenocortical Steroidogenesis in the Human Adrenal Carcinoma (HAC15) Cell Line

Afamin and adropin in patients with alcohol-induced liver cirrhosis

Adropin as a potential mediator of the metabolic system‐autonomic nervous system‐chronobiology axis: Implementing a personalized signature‐based platform for chronotherapy

Contact Info

Product

Resources

About